Transdermal cannabinoid formulations
US10028904B2 · kind B2 · utility
20Cited by
23References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2016 |
| Grant date | Jul 24, 2018 |
| Priority date | — |
| Expiry date | Jun 28, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.